More importantly, we utilized the METTL3‐14‐WTAP activator to restore SETMAR expression and promote the differentiation of thyroid cancer, thus providing a new method of redifferentiation therapy for treating patients with thyroid cancer. This evidence concerns the gene SETMAR and thyroid gland carcinoma.